Clinical utility of a blood-based BRAF V600E mutation assay in melanoma

BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treatment decisions. Blood BRAF(V600E) detection and qu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Cancer Ther
Auteurs principaux: Panka, David J, Buchbinder, Elizabeth, Giobbie-Hurder, Anita, Schalck, Aislyn P, Montaser-Kouhsari, Laleh, Sepehr, Alireza, Lawrence, Donald P., McDermott, David F., Cohen, Rachel, Carlson, Alexander, Wargo, Jennifer A, Merritt, Ryan, Seery, Virginia J., Hodi, F. Stephen, Gunturi, Anasuya, Fredrick, Dennie, Atkins, Michael B., Iafrate, A. John, Flaherty, Keith T., Mier, James W, Sullivan, Ryan J
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258469/
https://ncbi.nlm.nih.gov/pubmed/25319388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0349
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires